Genprex Statistics

Total Valuation

Genprex has a market cap or net worth of $5.35 million. The enterprise value is -$12.73 million.

Market Cap	5.35M
Enterprise Value	-12.73M

Important Dates

The next estimated earnings date is Thursday, August 13, 2026, after market close.

Earnings Date	Aug 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Genprex has 10.59 million shares outstanding. The number of shares has increased by 1,648.49% in one year.

Current Share Class	10.59M
Shares Outstanding	10.59M
Shares Change (YoY)	+1,648.49%
Shares Change (QoQ)	+229.76%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	1.29%
Float	10.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.27
P/TBV Ratio	0.31
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.61

Current Ratio	5.61
Quick Ratio	5.38
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-21.68

Financial Efficiency

Return on equity (ROE) is -160.84% and return on invested capital (ROIC) is -96.41%.

Return on Equity (ROE)	-160.84%
Return on Assets (ROA)	-76.19%
Return on Invested Capital (ROIC)	-96.41%
Return on Capital Employed (ROCE)	-94.62%
Weighted Average Cost of Capital (WACC)	-1.05%
Revenue Per Employee	n/a
Profits Per Employee	-$1.29M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -95.47% in the last 52 weeks. The beta is -0.96, so Genprex's price volatility has been lower than the market average.

Beta (5Y)	-0.96
52-Week Price Change	-95.47%
50-Day Moving Average	0.78
200-Day Moving Average	3.77
Relative Strength Index (RSI)	34.77
Average Volume (20 Days)	394,835

Short Selling Information

The latest short interest is 1.00 million, so 9.48% of the outstanding shares have been sold short.

Short Interest	1.00M
Short Previous Month	976,021
Short % of Shares Out	9.48%
Short % of Float	9.50%
Short Ratio (days to cover)	3.34

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-16.04M
Pretax Income	-16.73M
Net Income	-16.73M
EBITDA	n/a
EBIT	-16.04M
Earnings Per Share (EPS)	-$6.45

Full Income Statement

Balance Sheet

The company has $18.05 million in cash and n/a in debt, giving a net cash position of $18.05 million or $1.70 per share.

Cash & Cash Equivalents	18.05M
Total Debt	n/a
Net Cash	18.05M
Net Cash Per Share	$1.70
Equity (Book Value)	16.93M
Book Value Per Share	1.87
Working Capital	15.45M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-14.29M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	-14.29M
FCF Per Share	-$1.35

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Genprex does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,648.49%
Shareholder Yield	-1,648.49%
Earnings Yield	-314.74%
FCF Yield	-268.86%

Analyst Forecast

The average price target for Genprex is $375.00, which is 74,157.43% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$375.00
Price Target Difference	74,157.43%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Splits

The last stock split was on October 21, 2025. It was a reverse split with a ratio of 1:50.

Last Split Date	Oct 21, 2025
Split Type	Reverse
Split Ratio	1:50

Scores

Altman Z-Score	n/a
Piotroski F-Score	2